Adagrasib is Used for treating locally advanced or metastatic non-small cell lung cancer in adult patients with a specific KRAS mutation who have already undergone prior systemic therapy. It was first introduced by Mirati Therapeutics Inc in its drug Krazati on Dec 12, 2022.

Adagrasib Patents

Given below is the list of patents protecting Adagrasib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Krazati	US10689377	KRas G12C inhibitors	May 17, 2037	Mirati Theraps

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳